Key Points
- CEO William Quinn sold 6,545 shares of Bolt Biotherapeutics at an average price of $3.32, totaling $21,729.40 and reducing his stake by 15.94%. The sale was made to cover tax withholding on vested equity awards.
- Bolt shares opened at $3.59, with a market capitalization of approximately $6.93 million, after trading between $3.10 and $7.20 over the past year. The company reported a quarterly loss of $4.57 per share, missing estimates by $1.18.
- Analyst sentiment is mixed, with a consensus rating of Hold and an average price target of $14.50; institutional investors own approximately 86.7% of the stock.
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT - Get Free Report) VP Sarah Nemec sold 4,077 shares of the company's stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $3.24, for a total value of $13,209.48. Following the completion of the sale, the vice president owned 17,082 shares in the company, valued at approximately $55,345.68. This represents a 19.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Sarah Nemec also recently made the following trade(s):
- On Thursday, September 17th, Sarah Nemec sold 2,922 shares of Bolt Biotherapeutics stock. The shares were sold at an average price of $3.32, for a total value of $9,701.04.
- On Wednesday, September 16th, Sarah Nemec sold 843 shares of Bolt Biotherapeutics stock. The stock was sold at an average price of $3.77, for a total value of $3,178.11.
Bolt Biotherapeutics Price Performance
Bolt Biotherapeutics stock opened at $3.59 on Tuesday. The firm has a market capitalization of $6.93 million, a PE ratio of -0.22 and a beta of 1.09. Bolt Biotherapeutics, Inc. has a 52 week low of $3.10 and a 52 week high of $7.20. The firm's 50-day simple moving average is $3.83 and its 200 day simple moving average is $4.29. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 1.47.
Bolt Biotherapeutics (NASDAQ:BOLT - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($4.57) earnings per share for the quarter, missing the consensus estimate of ($3.39) by ($1.18). The business had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.50 million. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. On average, equities research analysts predict that Bolt Biotherapeutics, Inc. will post -11.1 EPS for the current fiscal year.
Hedge Funds Weigh In On Bolt Biotherapeutics
Several institutional investors and hedge funds have recently bought and sold shares of BOLT. Nan Fung Group Holdings Ltd purchased a new stake in shares of Bolt Biotherapeutics during the 2nd quarter valued at $19,250. Renaissance Technologies LLC raised its position in shares of Bolt Biotherapeutics by 40.3% in the 1st quarter. Renaissance Technologies LLC now owns 77,225 shares of the company's stock worth $312,000 after buying an additional 22,200 shares during the period. Finally, T3 Companies LLC acquired a new position in Bolt Biotherapeutics in the fourth quarter valued at $208,000. Institutional investors and hedge funds own 86.70% of the company's stock.
Key Stories Impacting Bolt Biotherapeutics
Here are the key news stories impacting Bolt Biotherapeutics this week:
- Positive Sentiment: The reported sales by CEO William Quinn, VP Sarah Nemec, and COO Grant Yonehiro were made to cover tax-withholding obligations tied to vested equity awards, rather than being identified as discretionary open-market selling. This may reduce the negative signal typically associated with insider sales. SEC insider-trading filing
- Neutral Sentiment: Insiders collectively reported selling approximately 38,600 shares for about $128,400 from September 16–18. Because the transactions were connected to tax withholding, the activity appears largely administrative, although it reduces executive ownership.
- Neutral Sentiment: Earlier filings showed CEO William Quinn and VP Sarah Nemec purchasing a combined 1,146 shares on June 5 at $3.88 per share. Those purchases provide some evidence of insider participation, but they were substantially smaller and occurred several months before the latest sales. SEC insider-trading filing
- Negative Sentiment: The latest filings show ownership declines across the CEO, VP, and COO, including reductions of roughly 26%, 19%, and 28%, respectively, in individual transactions. Even when tax-related, broad selling by multiple senior executives can weigh on investor sentiment and may limit upside in the near term.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on BOLT. Weiss Ratings restated a "sell (e+)" rating on shares of Bolt Biotherapeutics in a research report on Friday, July 17th. HC Wainwright reissued a "buy" rating and issued a $7.00 price objective on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. Finally, Rodman & Renshaw began coverage on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. They set a "buy" rating and a $22.00 price objective on the stock. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $14.50.
View Our Latest Stock Report on Bolt Biotherapeutics
Bolt Biotherapeutics Company Profile
(
Get Free Report)
Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company's platform is designed to stimulate the body's innate and adaptive immune systems to recognize and attack tumor cells.
Bolt's technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment.
The company's development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
